Overview
NAD+ is classified as a longevity peptide. Cellular energy, DNA repair, longevity.
NAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
Also known as: Nicotinamide Adenine Dinucleotide, NAD Plus, Beta-Nicotinamide Adenine Dinucleotide
Category
Longevity
Half-Life
4h
Route
SubQ
FDA Status
Not Approved
How Does NAD+ Work?
NAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
At the molecular level, NAD+ operates through pathways characteristic of the Longevity class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]NAD+ decline is a driver of aging
Rajman et al. (Cell Metabolism): Comprehensive review demonstrating NAD+ decline as a hallmark of aging, with restoration improving mitochondrial function, stem cell renewal, and lifespan in animal models.
Evidence: strong[2]NAD+ repletion improves mitochondrial and stem cell function
Zhang et al. (Science): NAD+ supplementation restores mitochondrial function in aged mice, improving muscle stem cell function and extending lifespan.
Evidence: preclinical[3]CD38 dictates age-related NAD decline and mitochondrial dysfunction
Camacho-Pereira et al. (Cell Metabolism): Identifies CD38 as the primary NAD-consuming enzyme that increases with age, explaining the progressive NAD+ decline.
Evidence: preclinical[4]NAD+ intermediates: NMN and NR clinical trial overview
Yoshino et al.: Review of human clinical trials for NAD+ precursors (NMN, NR) showing safe elevation of blood NAD+ levels with improvements in insulin sensitivity and muscle function.
Evidence: moderateSafety Profile
Generally well-tolerated. IV NAD+ infusions may cause chest tightness, nausea, and cramping during administration. Subcutaneous injection is better tolerated. Oral precursors (NMN, NR) have good safety profiles in clinical trials.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea during infusion | ~30% (IV route) | moderate |
| Flushing/warmth | ~20% of users | mild |
| Chest tightness | ~15% (IV route) | mild |
| Injection site discomfort | ~10% (SubQ) | mild |
Sourcing NAD+ for Research
If you're looking to source NAD+ for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
NAD+ — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.